SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Cutting the cost of drug development? · Study

ReviewCutting the cost of drug development?

M. D. Rawlins2004

Review2004

Cutting the cost of drug development?

187 citations·0/0 files stored·Nature Reviews Drug Discovery

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Pharmaceutical industry and healthcare Biomedical Ethics and Regulation

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 187 citations exist upstream.

References

2003The price of innovation: new estimates of drug development costs 2000Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs 1994Returns to R&D on new drug introductions in the 1980s

Cited by

2013The risks of risk aversion in drug regulation 2011The Cost-Effectiveness of Drug Regulation: The Example of Thorough QT/QTc Studies 2008Making a difference: 30 years of TDR 2011Drug discovery management, small is still beautiful: Why a number of companies get it wrong 2012The Impact of Effective Patents on Future Innovations in Nanomedicine 2025Clinician guidance in digital therapeutics for panic disorder: Meta-analytic dissection and implications for regulatory framing and scalable deployment

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

2007Generic competition and market exclusivity periods in pharmaceuticalsarticle · 2 shared references 2005Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industryarticle · 2 shared references 2015The Cost of Drug Developmentarticle · 2 shared references 2008Follow-on biologics: data exclusivity and the balance between innovation and competitionreview · 2 shared references 2004Cost-Effectiveness And Evidence Evaluation As Criteria For Coverage Policyarticle · 2 shared references 2011The Pragmatist's Guide to Comparative Effectiveness Researcharticle · 2 shared references

Details

Year2004

Typereview

Published2004-04-01

VenueNature Reviews Drug Discovery

ISSN-L1474-1776

Languageen

Citations187

Files0 public / 0

ShelfPharmaceutical Economics and Policy

Identifiers

doi10.1038/nrd1347

openalex_workW2009291347

Links

Imported from OpenAlex (CC0) — nothing here is generated.